As of 2025-07-11, the Intrinsic Value of Bicara Therapeutics Inc (BCAX) is -9.61 USD. This BCAX valuation is based on the model Peter Lynch Fair Value. With the current market price of 9.92 USD, the upside of Bicara Therapeutics Inc is -196.89%.
Based on its market price of 9.92 USD and our intrinsic valuation, Bicara Therapeutics Inc (BCAX) is overvalued by 196.89%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -9.61 - -9.61 | -9.61 | -196.89% |
| DDM - Stable | (8.36) - (16.40) | (12.38) | -224.8% |
| DDM - Multi | (4.15) - (6.48) | (5.07) | -151.1% |
| Market Cap (mil) | 541.04 |
| Beta | 1.67 |
| Outstanding shares (mil) | 54.54 |
| Enterprise Value (mil) | 78.97 |
| Market risk premium | 4.60% |
| Cost of Equity | 17.32% |
| Cost of Debt | 5.00% |
| WACC | 11.16% |